Core Viewpoint - The company reported significant growth in revenue and net profit for the year 2025, indicating a successful year driven by innovative product launches and effective cost management [2][4]. Financial Performance - The company achieved an operating revenue of 542.11 million yuan, representing a 71.23% increase compared to the previous year [2][4]. - The net profit attributable to the parent company was 80.62 million yuan, with a net profit excluding non-recurring gains and losses of 65.14 million yuan, marking a turnaround from losses in the previous year [2][5]. - Total assets at the end of the reporting period were 945.61 million yuan, reflecting a 20.77% increase from the beginning of the period [2]. Factors Influencing Performance - The company's core products gained widespread recognition for their clinical value, entering over 60 countries and regions, and being applied in more than 2,000 hospitals [3]. - International business revenue grew by over 130%, contributing to an increased share of total revenue [3]. - The company focused on research and development, particularly in the fields of intelligent and precise interventional treatment, which supported sustainable long-term growth [3]. - Effective control of operating expenses and a growing product pipeline contributed to the significant improvement in profitability [4][5]. Key Metrics Changes - The operating revenue increased by 71.23% year-on-year, driven by the successful launch and clinical application of innovative products [4]. - The operating profit and total profit also saw substantial growth due to increased sales and effective cost management [4]. - Basic earnings per share and the weighted average return on equity both showed significant increases, reflecting the overall profitability turnaround [5].
深圳北芯生命科技股份有限公司2025 年度业绩快报公告